14 November 2025 - The outcome statement from the October 2025 DUSC meeting is now available.

The DUSC reviewed the following technologies:

• Daratumumab with hyaluronidase (human, recombinant) for amyloidosis
• Elexacaftor with tezacaftor and ivacaftor for cystic fibrosis
• Medicines for chronic lymphocytic leukaemia or small lymphocytic lymphoma

Read PBS News